The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...

AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

In the FTSE All-Share, DFS Furniture jumped 11% or 13.8p to 145p after reporting an acceleration in order intake at the start ...

In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

The AstraZeneca PLC ADR AZN slid 2.30% to $74.24 Tuesday, on what proved to be an all-around dismal trading session for the ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...